Is Twist Bioscience (TWST) Fairly Valued As Its Shares Rebound?

Twist Bioscience (TWST) is back on investor screens after a sharp single day move of 5.1%, following a volatile week that saw the share price drop 15.3%.

That rebound comes after a steep 7 day share price return of down 15.3%, which still sits against a powerful year to date share price gain of 393.3% and a 1 year total shareholder return of 412.3%, suggesting that momentum has been strong even as short term sentiment cools.

Scan beyond Twist Bioscience's surge to see how other high momentum compounders stack up in the 20 high quality undiscovered gems list before the next sharp move hits your watchlist.

After a 5.1% jump that still leaves Twist Bioscience trading above the average analyst target yet at a discount to some intrinsic estimates, is the market showing discipline or mispricing the risk that recent enthusiasm has overlooked?

Most Popular Narrative: 46% Overvalued

The most followed narrative puts Twist Bioscience’s fair value at $109.58, well below the last close at $159.78, which sets a high bar for everything that comes next in the story.

Diversification across multiple end markets and geographies, coupled with strong underlying industry trends like AI driven drug discovery and global genomics market expansion, provides resilience against market cycles and supports steady, long-term revenue and profit growth.

Find out how 23 investors see Twist Bioscience as 46% overvalued.

Result: Fair Value of $109.58 (OVERVALUED)

Still, Twist Bioscience faces clear pressure points, including ongoing losses of $136.7 million and heavy reliance on a handful of large NGS customers.

Find out about the key risks to this Twist Bioscience narrative.

Another View: DCF Points in the Other Direction

The analyst narrative tags Twist Bioscience as 46% overvalued at $159.78 against a $109.58 fair value, yet the SWS DCF model tells a different story. Through that lens, the stock trades about 27.1% below an estimated future cash flow value of $219.20. Which lens do you trust more when cash burn and growth expectations pull in opposite directions?

For a closer look at how those cash flows were modeled and discounted, take a moment with the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Twist Bioscience so far. If the crosscurrents between enthusiasm and concern feel familiar, move quickly, test the numbers, and weigh the 2 key rewards and 3 important warning signs.

Looking for more ideas beyond Twist Bioscience?

If Twist Bioscience has sharpened your interest, widen the search now with fresh screeners that surface opportunities before they hit everyone else’s radar.

• Spot potential bargains early and let valuation work for you through a curated set of 29 high quality undervalued stocks that pair quality with pricing discipline.
• Secure your downside first by focusing on capital strength with a focused list of solid balance sheet and fundamentals (25 results) that keeps weak finances off your shortlist.
• Stack the odds toward resilience by filtering for 31 resilient stocks with low risk scores so sudden shocks are less likely to blindside your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com